Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 19Tumor-Agnostic 6Sarcoma 6Gastrointestinal 3Genitourinary 2NET 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Melanoma 75Neoplasm Metastasis 9Brain Neoplasms 9Uveal Melanoma 7Skin Neoplasms 5Breast Neoplasms 4Glioblastoma 2Central Nervous System Neoplasms 2Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Second Primary 1Neoplasms 1Mycosis Fungoides 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma, Cutaneous Malignant 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Temozolomide × Dermatologic × Clear all
NCT00588341 2016-02-01

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
24 enrolled 4 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡